GlassScriptPhysician profile
Jillian E Rogers
NPI 1184902306
$2,711.69
in general payments reported to CMS, 2019-2025
25 companies · $71.72 in 2025
The $71.72 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $883 · 2022: $897 · 2023: $663 · 2024: $197 · 2025: $71.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $746.04 | 2021-2024 | |
| Lilly USA, LLC | $421.65 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $395.59 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.94 | 2021-2023 | Synjardy, Tradjenta, Stiolto Respimat |
| Glaxosmithkline, LLC. | $142.02 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $116.01 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $110.08 | 2021-2024 | Farxiga |
| Pfizer INC. | $99.00 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.02 | 2021-2023 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $49.94 | 2021 | |
| Merck Sharp & Dohme LLC | $43.04 | 2021-2025 | Gardasil 9, M-M-R II, Vaqta |
| Astellas Pharma US INC | $42.00 | 2022-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $39.55 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $34.76 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.46 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.01 | 2022 | |
| Phathom Pharmaceuticals, INC. | $22.15 | 2024 | Voquezna |
| Dexcom, INC. | $20.28 | 2023 | Dexcom G6 Transmitter |
| Acadia Pharmaceuticals INC | $18.72 | 2025 | Daybue |
| Abbott Laboratories | $18.53 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.56 | 2022 | |
| Eisai INC. | $14.84 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.60 | 2022 | |
| Sanofi Pasteur INC. | $12.99 | 2022 | |
| Biogen, INC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.